Ma Haixia, Li Xiaoyang, Li Jinxi, Bu Jie, Li Xianan, Zhang Jie, Yu Shengji, Nie Guangjun, Wang Hai, Feng Helin
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China; Department of Clinical Laboratory, Xuanwu Hospital, National Clinical Research Center for Geriatric Diseases, Capital Medical University, Beijing, 100053, China.
Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Biomaterials. 2026 Jan;324:123546. doi: 10.1016/j.biomaterials.2025.123546. Epub 2025 Jul 9.
Sarcomas are malignant tumors that display inter- and intra-tumoral heterogeneity. Patient-derived organoids enable the creation of systems that stably recapitulate many aspects of parental tumors in vitro. Thus, the idea of using patient-derived organoids for therapeutic screening and precision medicine is tantalizing. Here, we describe a biobank of soft tissue and bone sarcoma (STBS) organoid lines derived from patient tumor tissues. In total, we established 44 STBS organoid lines, representing eight subtypes of STBS. These STBS organoids faithfully recapitulate the histological features, mutational profiles, gene expression profiles, and cellular diversity of the corresponding tumors. STBS organoids can be used not only for screening chemotherapeutic and target therapeutic drugs, but also for predicting immune responses. Our data demonstrate the potential of STBS organoids for both basic research and for designing personalized sarcoma treatments.
肉瘤是表现出肿瘤间和肿瘤内异质性的恶性肿瘤。患者来源的类器官能够创建在体外稳定重现亲本肿瘤许多方面的系统。因此，使用患者来源的类器官进行治疗性筛选和精准医学的想法很诱人。在这里，我们描述了一个源自患者肿瘤组织的软组织和骨肉瘤（STBS）类器官系生物样本库。我们总共建立了44个STBS类器官系，代表了STBS的八个亚型。这些STBS类器官忠实地重现了相应肿瘤的组织学特征、突变谱、基因表达谱和细胞多样性。STBS类器官不仅可用于筛选化疗药物和靶向治疗药物，还可用于预测免疫反应。我们的数据证明了STBS类器官在基础研究和设计个性化肉瘤治疗方面的潜力。
